McKesson MCK Business Segments
| Q4 '26 | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Business | ||||||
| Medical-Surgical Solutions | $2.87B-4.1% | $2.99B+1.5% | $2.95B+9.1% | $2.7B-5.3% | $2.85B-3.3% | |
| North American Pharmaceutical | $79.12B-10.4% | $88.32B+2.1% | $86.48B+4.5% | $82.73B+7.5% | $76.94B-5.2% | |
| Oncology & Multispecialty | $12.71B-2.3% | $13.01B+8.0% | $12.04B+13.0% | $10.66B+13.0% | $9.43B-0.7% | |
| Prescription Technology Solutions | $1.5B-0.3% | $1.5B+9.0% | $1.38B-4.0% | $1.43B+7.1% | $1.34B-2.3% | |
| Total long-lived assets by Geography | ||||||
| Foreign | $255M+0.4% | $254M-2.7% | $261M-20.9% | $330M+7.8% | $306M— | |
| United States | $3.18B+1.6% | $3.13B+1.0% | $3.1B+4.9% | $2.95B+2.6% | $2.88B— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does McKesson break its business down?
- McKesson (MCK) reports total revenues by business across 4 parts — Medical-Surgical Solutions, North American Pharmaceutical, Oncology & Multispecialty and Prescription Technology Solutions. Each is extracted from the segment footnotes and tracked over time.
- Where does McKesson's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in McKesson's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
